JPS5592325A - Antitumor agent and its preparation - Google Patents

Antitumor agent and its preparation

Info

Publication number
JPS5592325A
JPS5592325A JP16138878A JP16138878A JPS5592325A JP S5592325 A JPS5592325 A JP S5592325A JP 16138878 A JP16138878 A JP 16138878A JP 16138878 A JP16138878 A JP 16138878A JP S5592325 A JPS5592325 A JP S5592325A
Authority
JP
Japan
Prior art keywords
antitumor
active constituent
substance
antibody
antitumor agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP16138878A
Other languages
English (en)
Other versions
JPS6254086B2 (ja
Inventor
Chikao Yoshikumi
Takami Fujii
Masahiko Fujii
Kenichi Matsunaga
Yoshiharu Oguchi
Koichi Niimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Priority to JP16138878A priority Critical patent/JPS5592325A/ja
Priority to US06/103,474 priority patent/US4315851A/en
Priority to ZA00796896A priority patent/ZA796896B/xx
Priority to SE7910483A priority patent/SE7910483L/xx
Priority to PH23447A priority patent/PH16902A/en
Priority to AU54144/79A priority patent/AU518952B2/en
Priority to BE6/47054A priority patent/BE880970A/fr
Priority to FR797932054A priority patent/FR2445149B1/fr
Priority to CH11501/79A priority patent/CH655010A5/de
Priority to GB7944494A priority patent/GB2038836B/en
Priority to DE2952690A priority patent/DE2952690C2/de
Priority to IT28464/79A priority patent/IT1127324B/it
Publication of JPS5592325A publication Critical patent/JPS5592325A/ja
Priority to US06/321,486 priority patent/US4401592A/en
Priority to SE8406510A priority patent/SE8406510L/xx
Priority to SE8406511A priority patent/SE8406511D0/xx
Publication of JPS6254086B2 publication Critical patent/JPS6254086B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP16138878A 1978-12-29 1978-12-29 Antitumor agent and its preparation Granted JPS5592325A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP16138878A JPS5592325A (en) 1978-12-29 1978-12-29 Antitumor agent and its preparation
US06/103,474 US4315851A (en) 1978-12-29 1979-12-14 Pharmaceutical composition having antitumor activity
ZA00796896A ZA796896B (en) 1978-12-29 1979-12-19 Pharmaceutical composition having antitumor activity
SE7910483A SE7910483L (sv) 1978-12-29 1979-12-19 Farmaceutisk komposition med tumorhemmande effekt
PH23447A PH16902A (en) 1978-12-29 1979-12-20 Pharmaceutical composition having anti-tumor activity
AU54144/79A AU518952B2 (en) 1978-12-29 1979-12-21 Antitumour composition
FR797932054A FR2445149B1 (fr) 1978-12-29 1979-12-28 Composition pharmaceutique ayant une activite antitumorale
BE6/47054A BE880970A (fr) 1978-12-29 1979-12-28 Composition pharmaceutique ayant une activite antitumorale
CH11501/79A CH655010A5 (de) 1978-12-29 1979-12-28 Pharmazeutischer wirkstoff mit antitumoraktivitaet.
GB7944494A GB2038836B (en) 1978-12-29 1979-12-28 Antitumour substance
DE2952690A DE2952690C2 (de) 1978-12-29 1979-12-29 Antitumorsubstanz, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Mittel
IT28464/79A IT1127324B (it) 1978-12-29 1979-12-31 Composizione farmaceutica avente attivita' antitumorale
US06/321,486 US4401592A (en) 1978-12-29 1981-11-16 Pharmaceutical composition having antitumor activity
SE8406510A SE8406510L (sv) 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt
SE8406511A SE8406511D0 (sv) 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16138878A JPS5592325A (en) 1978-12-29 1978-12-29 Antitumor agent and its preparation

Publications (2)

Publication Number Publication Date
JPS5592325A true JPS5592325A (en) 1980-07-12
JPS6254086B2 JPS6254086B2 (ja) 1987-11-13

Family

ID=15734135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16138878A Granted JPS5592325A (en) 1978-12-29 1978-12-29 Antitumor agent and its preparation

Country Status (4)

Country Link
JP (1) JPS5592325A (ja)
AU (1) AU518952B2 (ja)
BE (1) BE880970A (ja)
ZA (1) ZA796896B (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59134734A (ja) * 1983-01-19 1984-08-02 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
JPS6041617A (ja) * 1983-08-18 1985-03-05 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造法
JPS62116524A (ja) * 1983-04-08 1987-05-28 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448663A (en) * 1982-07-06 1984-05-15 The Dow Chemical Company Double L-shaped electrode for brine electrolysis cell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (ja) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (ja) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS6256136B2 (ja) * 1979-11-02 1987-11-24 Kureha Chemical Ind Co Ltd
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59134734A (ja) * 1983-01-19 1984-08-02 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
JPS62116524A (ja) * 1983-04-08 1987-05-28 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
JPH0611713B2 (ja) * 1983-04-08 1994-02-16 呉羽化学工業株式会社 ヒト免疫グロブリン結合抗腫瘍剤
JPS6041617A (ja) * 1983-08-18 1985-03-05 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造法

Also Published As

Publication number Publication date
ZA796896B (en) 1980-11-26
BE880970A (fr) 1980-06-30
JPS6254086B2 (ja) 1987-11-13
AU5414479A (en) 1980-07-03
AU518952B2 (en) 1981-10-29

Similar Documents

Publication Publication Date Title
CA1064826A (en) Antigen binding dimer bound to drug
CA2017025A1 (en) Tumor necrosis factor binding protein ii, its purification and antibodies thereto
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0226419A3 (en) Anti-human ovarian cancer immunotoxins and methods of use thereof
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
IT8320548A0 (it) Anticorpi aventi doppie specificita', loro preparazione eloro impieghi.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
CA2081150A1 (en) Use of antibody-containing preparations for immunosuppression
AU8172094A (en) Synthetic HTLV-III peptides, compositions and uses thereof
EP0085334A3 (en) Substantive topical compositions
CA2182289A1 (en) Immuno-stimulatory monoclonal antibodies
JPS5592325A (en) Antitumor agent and its preparation
BG103416A (en) Soluble lymphotoxin-beta receptors, antilymphotosoluble lymphotoxin- receptors, antilymphotoxin receptor antibodies and antilymphotoxin ligand antixin receptor antibodies and antilymphotoxin ligandbodies as therapeutical forms for the treatment of antibodies as therapeutical forms for the treatment of immunological diseases immunological diseases
SE8303003D0 (sv) Medel for att oka antitumorverkan hos antitumormedel
RU93004535A (ru) Соединения, способ получения и фармацевтическая композиция на их основе
BR9710377A (pt) Gr-nulos de derivados de hexahidropirazina administr veis por via oral
EP0381504A3 (en) Improvements in and relating to guanidine derivatives
CA2066031A1 (en) Methods for reducing non-target retention of immunoconjugates and metabolites thereof
IT1092070B (it) Valvola per l'erogazione separata di due componenti e per la loro miscelazione all'esterno della stessa
TR22586A (tr) Ziral terkipler,zirai terkipleri hazirlama yoentemleri ve zirai terkipleri kullanma yoentemleri
JPS5665828A (en) Antitumor agent
CA2002218A1 (en) Neoglycoproteins, the preparation and use thereof
CA2091967A1 (en) Monoclonal anti-ganglioside antibody, its preparation and use as a tumor therapeutic agent